ABACAVIR SULFATE AND LAMIVUDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Abacavir Sulfate And Lamivudine, and when can generic versions of Abacavir Sulfate And Lamivudine launch?
Abacavir Sulfate And Lamivudine is a drug marketed by Mylan Labs Ltd, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Laurus, Teva Pharms Usa, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Abacavir Sulfate And Lamivudine
A generic version of ABACAVIR SULFATE AND LAMIVUDINE was approved as abacavir sulfate; lamivudine by CHARTWELL RX on March 28th, 2017.
Summary for ABACAVIR SULFATE AND LAMIVUDINE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 8 |
| Patent Applications: | 114 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ABACAVIR SULFATE AND LAMIVUDINE at DailyMed |
Recent Clinical Trials for ABACAVIR SULFATE AND LAMIVUDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| ViiV Healthcare | Phase 4 |
| Gilead Sciences | Phase 3 |
| GlaxoSmithKline | Phase 4 |
Pharmacology for ABACAVIR SULFATE AND LAMIVUDINE
Anatomical Therapeutic Chemical (ATC) Classes for ABACAVIR SULFATE AND LAMIVUDINE
US Patents and Regulatory Information for ABACAVIR SULFATE AND LAMIVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET, FOR SUSPENSION;ORAL | 204311-001 | Dec 22, 2023 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva Pharms Usa | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 079246-001 | Sep 29, 2016 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Chartwell Rx | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 204990-001 | Mar 28, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Zydus Pharms | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 208990-001 | Nov 15, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Aurobindo Pharma | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 206151-001 | Mar 28, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Aurobindo Pharma Ltd | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 090159-001 | Nov 15, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
